Home > Insider Trading > Filing (0001140361-25-022113)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	Biological Products, (No Disgnostic Substances) (2836)	562590442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1542519	B Jerrold Grossman	C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2025-06-09	10,000	$5.00	488,194	No	4	M	Direct
Common Stock	Disposition	2025-06-09	10,000	$21.31	478,194	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2025-06-09	10,000	$0.00	10,000	$5.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2027-02-14	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	22,857	Indirect	See footnote
Common Stock	31,381	Indirect	See footnote
Common Stock	38,294	Indirect	See footnote
Common Stock	175	Indirect	See footnote

Footnotes

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.29 to $21.35. The reporting person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which will vest in full on February 19, 2026, subject to the Reporting Person's continued service as of the applicable vesting date; and (ii) 467,305 shares of common stock owned by the reporting person.
These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
These shares are owned by the reporting person's wife.
These options were granted on February 14, 2017 and vested in twenty-four equal monthly installments, becoming fully vested on February 14, 2019.